×
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
NASDAQ:MDNA

Medicenna Therapeutics Stock Forecast, Price & News

$1.15
0.00 (0.00%)
(As of 07/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.14
$1.20
50-Day Range
$0.79
$1.32
52-Week Range
$0.76
$3.05
Volume
5,246 shs
Average Volume
95,418 shs
Market Capitalization
$64.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Medicenna Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
653.6% Upside
$8.67 Price Target
Short Interest
Healthy
0.35% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.08mentions of Medicenna Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.27) to ($0.31) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.61 out of 5 stars

Medical Sector

902nd out of 1,433 stocks

Pharmaceutical Preparations Industry

447th out of 683 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive MDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Medicenna Therapeutics logo

About Medicenna Therapeutics (NASDAQ:MDNA) Stock

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

MDNA Stock News Headlines

Medicenna Therapeutics (NASDAQ:MDNA) PT Lowered to $10.00
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MDNA
Employees
13
Year Founded
N/A

Company Calendar

Last Earnings
6/22/2022
Today
7/07/2022
Next Earnings (Estimated)
8/12/2022
Fiscal Year End
3/31/2023

Price Target and Rating

Average Stock Price Forecast
$8.67
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+595.7%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
3 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$64.75 million
Optionable
Not Optionable
Beta
0.88














Medicenna Therapeutics Frequently Asked Questions

Should I buy or sell Medicenna Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medicenna Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Medicenna Therapeutics stock.
View analyst ratings for Medicenna Therapeutics
or view top-rated stocks.

What is Medicenna Therapeutics' stock price forecast for 2022?

3 Wall Street research analysts have issued 12 month price targets for Medicenna Therapeutics' shares. Their MDNA stock forecasts range from $5.00 to $11.00. On average, they predict Medicenna Therapeutics' share price to reach $8.67 in the next year. This suggests a possible upside of 653.6% from the stock's current price.
View analysts' price targets for Medicenna Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Medicenna Therapeutics' stock price performed in 2022?

Medicenna Therapeutics' stock was trading at $1.63 at the beginning of the year. Since then, MDNA stock has decreased by 29.4% and is now trading at $1.15.
View the best growth stocks for 2022 here
.

When is Medicenna Therapeutics' next earnings date?

Medicenna Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022.
View our earnings forecast for Medicenna Therapeutics
.

How were Medicenna Therapeutics' earnings last quarter?

Medicenna Therapeutics Corp. (NASDAQ:MDNA) released its quarterly earnings data on Wednesday, June, 22nd. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.03.
View Medicenna Therapeutics' earnings history
.

Who are Medicenna Therapeutics' key executives?

Medicenna Therapeutics' management team includes the following people:
  • Dr. Fahar Merchant Ph.D., Founder, Chairman, Pres & CEO (Age 65, Pay $358.54k)
  • Ms. Rosemina Merchant B.Sc., M.E.Sc, Founder, Chief Devel. Officer & Director (Age 65, Pay $287.52k)
  • Ms. Elizabeth Williams C.A., CPA, CA, CPA, CFO & Corp. Sec. (Age 44, Pay $241.27k)
  • Dr. Martin Bexon M.D., MBBS, Acting Chief Medical Officer & Head of Clinical Devel.
  • Dr. Samuel R. Denmeade M.D., Scientific Advisor

What is Medicenna Therapeutics' stock symbol?

Medicenna Therapeutics trades on the NASDAQ under the ticker symbol "MDNA."

How do I buy shares of Medicenna Therapeutics?

Shares of MDNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Medicenna Therapeutics' stock price today?

One share of MDNA stock can currently be purchased for approximately $1.15.

How much money does Medicenna Therapeutics make?

Medicenna Therapeutics (NASDAQ:MDNA) has a market capitalization of $64.75 million. The company earns $-18,010,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis.

How many employees does Medicenna Therapeutics have?

Medicenna Therapeutics employs 13 workers across the globe.

How can I contact Medicenna Therapeutics?

Medicenna Therapeutics' mailing address is 200-1920 Yonge Street, Toronto A6, M4S 3E2. The official website for Medicenna Therapeutics is www.medicenna.com. The company can be reached via phone at (416) 648-5555, via email at ir@medicenna.com, or via fax at 416-572-7501.

This page (NASDAQ:MDNA) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.